PHI with Obstructive pulmonary emphysema
How does this condition affect your private health insurance?
Emphysem pulmonal obturierend, commonly known as obstructive pulmonary emphysema, is a chronic, progressive lung disease primarily characterized by the irreversible enlargement of air spaces distal to the terminal bronchioles, accompanied by destruction of their walls without obvious fibrosis. This damage leads to a loss of elasticity in the lungs, making exhalation difficult and trapping air, thus impairing gas exchange. Symptoms include chronic shortness of breath, coughing, and wheezing, worsening over time. It is strongly associated with long-term exposure to irritants, most notably cigarette smoke, and significantly reduces lung function and quality of life.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Develops insidiously over years, often noticed only when significant lung damage has occurred, typically chronic at diagnosis.
Duration of Illness (Lifetime)
Chronic and progressive, lifelong.
Cost of Treatment (Initial)
Initial diagnostic workup (imaging, pulmonary function tests) and medication can range from 500 to 2000 USD, depending on severity and region.
Cost of Treatment (Lifetime)
High, potentially tens of thousands to hundreds of thousands USD, including medications, oxygen therapy, rehabilitation, and possible hospitalizations.
Mortality Rate
Significant, particularly in advanced stages, with a 5-year mortality rate varying from 30% to over 50% depending on disease severity and complications.
Risk of Secondary Damages
Very high (e.g., cor pulmonale, recurrent respiratory infections, severe hypoxemia, cachexia, osteoporosis, depression).
Probability of Full Recovery
Extremely low; lung damage is largely irreversible. Treatment focuses on symptom management and slowing progression.
Underlying Disease Risk
High, often co-exists with chronic bronchitis (forming COPD), heart disease, and increased risk of lung cancer.